Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

755 - Activity of S-1 for non-small cell lung cancer pretreated with pemetrexed


20 Dec 2015


Poster presentation 2


Yoshiro Nakahara


Annals of Oncology (2015) 26 (suppl_9): 125-147. 10.1093/annonc/mdv532


Y. Nakahara1, Y. Takagi2, M. Nagamata2, K. Watanabe2, S. Takahashi2, M. Yomota2, Y. Okuma2, Y. Hosomi2, T. Okamura2, N. Masuda1

Author affiliations

  • 1 Department Of Respiratory Medicine, Kitasato University School of Medicine,, 252-0374 - Sagamihara/JP
  • 2 Department Of Thoracic Oncology And Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 113-8677 - Tokyo/JP


Abstract 755


The 5-fluorouracil derivative S-1 and pemetrexed (PEM) are antimetabolites that mainly target thymidylate synthase. S-1 received approval for treating non-small cell lung cancer (NSCLC) in Japan in December 2004, and has primarily been administered alone for salvage chemotherapy. To our knowledge, whether PEM resistance influences clinical S-1 activity is unavailable.


Patients with pretreated NSCLC who later underwent S-1 monotherapy were identified from an institutional database. Progression-free survival (PFS) and overall survival (OS) rates after S-1 administration were compared with respect to histological findings using the Kaplan-Meier method and log-rank tests. The PFS and OS rates of patients pretreated with PEM (PEM+) or without (PEM-) for non-squamous NSCLC (n-sq NSCLC) were also compared. The effects of clinical factors on PFS and OS were evaluated using univariate and multivariate analyses with Cox proportional-hazards models.


Among 12 patients (median age, 69 y; range, 39–86 y; female, 33%) who underwent S-1 monotherapy after pretreatment for NSCLC, 65 received PEM-based chemotherapy before S-1 administration. The histological subtypes were adenocarcinoma (65%), squamous cell carcinoma (SCC; 27%) and NSCLC not otherwise specified (8%). Among the patients, 25%, 40%, 25% and 10% had undergone one, two, three and four or more prior chemotherapy regimens, respectively. The median PFS was significantly better for patients with SCC than with n-sq NSCLC (3.4 vs. 2.1 months; HR, 0.62; 95% CI, 0.42–0.90; p = 0.01). Multivariate analysis selected only histology as a statistically significant predictor of a longer PFS. However, median OS did not significantly differ (SCC 8.4 vs. n-sq NSCLC 5.9 months; HR, 0.97; 95% CI, 0.65–1.40; p = 0.86). The PFS were similar between the PEM+ and PEM- groups among the 111 patients with n-sq NSCLC (median 2.1 vs. 2.0 months; HR, 1.17; 95% CI, 0.79–1.74; p = 0.44). The median OS for the PEM+ and PEM- groups were 6.8 and 4.9 months, respectively, not significantly different (HR, 0.70; 95% CI, 0.47–1.06; p = 0.08).


S-1 monotherapy was more effective for SCC than n-sq NSCLC, and prior PEM therapy did not affect S-1 activity in patients with n-sq NSCLC. Further study is warranted.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings